ARS Pharmaceuticals amends manufacturing agreement with Renaissance Lakewood for neffy nasal spray

ARS Pharmaceuticals, Inc.

Second amendment to manufacturing agreement for neffy executed September 17, 2024.
Initial term extended to five years after U.S. commercial launch and five years after EU launch, with automatic two-year renewals.
Termination provisions revised for breach, insolvency, regulatory denial/withdrawal, force majeure, and trade law violations.
Agreement covers neffy (epinephrine nasal spray) for anaphylaxis treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.